NCT06823167View on ClinicalTrials.gov

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

February 28, 2029

Conditions
Solid MalignanciesHematologic Malignancies
Interventions
BIOLOGICAL

IM-1021

IM-1021 is an antibody-drug conjugate

Trial Locations (7)

37203

RECRUITING

Sarah Cannon Research Institute - Oncology Partners, Nashville

48109

RECRUITING

University of Michigan, Ann Arbor

49546

RECRUITING

START Midwest, Grand Rapids

75039

RECRUITING

NEXT Oncology, Irving

77030

RECRUITING

MD Anderson Cancer Center, Houston

91010

RECRUITING

City Of Hope, Duarte

06510

RECRUITING

Yale University Medical Center, New Haven

Sponsors

Lead Sponsor

Immunome, Inc.
All Listed Sponsors
lead

Immunome, Inc.

INDUSTRY